



Docket No.: RLL-459US Serial No.: 10/593,939

Applicants: CHUGH et al.

Filed: 2/25/2006

Group: 1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,377,584	3/22/1983	Rasmussen et al.	424	258	
	A2	4,760,071	7/26/1988	Rasmussen et al.	514	284	
	A3	5,017,568	5/21/1991	Holt et al.	514	173	
	A4	5,096,890	3/17/1992	Cross et al.	514	422	
	A5	5,155,107	10/13/1992	Panzeri et al.	514	232.8	
	A6	5,233,053	8/3/1993	Cross et al.	548	568	
	A7	5,403,847	4/4/1995	Gluchowski et al.	514	318	
	A8	5,565,467	10/15/1996	Batchelor et al.	514	284	
	A9	5,578,611	11/26/1996	Gluchowski et al.	514	318	
	A10	5,595,985	1/21/1997	Labrie	514	169	
	A11	5,780,485	7/14/1998	Gluchowski et al.	514	318	
	A12	5,990,128	11/23/1999	Gluchowski et al.	514	318	
	A13	6,015,819	1/18/2000	Gluchowski et al.	514	318	
	A14	6,274,583	8/14/2001	Patane et al.	514	255	
	A15	6,376,503	4/23/2002	Patane et al.	514	274	
	A16	6,410,554	6/25/2002	Brotен et al.	514	299	
	A17	6,423,719	7/23/2002	Lawyer	514	263	
	A18	2001/0044438	11/22/2001	Wyllie	514	252.17	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	EP 0 325 571	7/26/1989	EPO	C07C	215/54	
	B2	EP 0 388 054	9/19/1990	EPO	C07D	207/08	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION				Docket No.: RLL-459US	Serial No.: 10/593,939	
				Applicants: CHUGH et al.		
				Filed: 2/25/2006		Group: 1617

B3	EP 0 572 165	12/1/1993	EPO	C07J	73/00	
B4	EP 0 572 166	12/1/1993	EPO	C07J	73/00	
B5	EP 0 801 067	10/15/1997	EPO	C07D	453/02	
B6	EP 1 123 705	8/16/2001	EPO	A61K	31/505	
B7	GB 940,540	10/30/1963	UK	C07C		
B8	WO 93/23038	11/25/1993	PCT	A61K	31/435	
B9	WO 93/23039	11/25/1993	PCT	A61K	31/435	
B10	WO 93/23040	11/25/1993	PCT	A61K	31/435	
B11	WO 93/23041	11/25/1993	PCT	A61K	31/435	
B12	WO 93/23048	11/25/1993	PCT	A61K	31/45	
B13	WO 93/23050	11/25/1993	PCT	A61K	31/495	
B14	WO 93/23051	11/25/1993	PCT	A61K	31/495	
B15	WO 93/23376	11/25/1993	PCT	C07D	215/00	
B16	WO 93/23419	11/25/1993	PCT	C07J	73/00	
B17	WO 93/23420	11/25/1993	PCT	C07J	73/00	
B18	WO 96/40136	12/19/1996	PCT	A61K	31/445	
B19	WO 98/05641	2/12/1998	PCT	C07D	211/46	
B20	WO 98/57638	12/23/1998	PCT	A61K	31/445	
B21	WO 99/57131	11/11/1999	PCT	C07H	21/04	
B22	WO 01/21167	3/29/2001	PCT	A61K	31/13	
B23	WO 02/44151	6/6/2002	PCT	C07D	209/48	
B24	WO 03/084928	10/16/2003	PCT	C07D	209/48	
B25	WO 2004/004629	1/15/2004	PCT	A61K		
B26	WO 2004/014853	2/19/2004	PCT	C07D	209/02	
B27	WO 2004/018422	3/4/2004	PCT	C07D	209/52	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-459US	Serial No.: 10/593,939
	Applicants: CHUGH et al.	
	Filed: 2/25/2006	Group: 1617

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Berry et al., "The development of Human Benign Prostatic Hyperplasia With Age", <i>The Journal of Urology</i> , <u>132</u> :474-479 (1984)
C2	Speakman, "Initial Choices and Final Outcomes in Lower Urinary Tract Symptoms", <i>European Urology</i> , <u>40</u> (Suppl. 4):21-30 (2001)
C3	Shapiro et al., "The Relative Proportion of Stromal and Epithelial Hyperplasia is Related to the Development of Symptomatic Benign Prostate Hyperplasia", <i>The Journal of Urology</i> , <u>147</u> :1293-1297 (1992)
C4	Caine, "The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy", <i>The Journal of Urology</i> , <u>136</u> :1-4 (1986)
C5	Andersson, "Mode of action of α_1 -adrenoreceptor antagonists in the treatment of lower urinary tract symptoms", <i>BJU International</i> , <u>85</u> (Suppl. 2):12-18 (2000)
C6	Wilde and Goa, "Finasteride: An Update of its Use in the Management of Symptomatic Benign Prostatic Hyperplasia", <i>Drugs</i> , <u>57</u> (4):557-581 (1999)
C7	Chapple, " α -adrenergic blocking drugs in bladder outflow obstruction: what potential has α_1 -adrenoceptor selectivity?", <i>British Journal of Urology</i> , <u>76</u> (Suppl. 1):47-55 (1995)
C8	Kawabe and Niijima, "Use of an α_1 -Blocker, YM-12617, in Micturition Difficulty", <i>Urologia Internationalis</i> , <u>42</u> :280-284 (1987)
C9	Lepor et al., "A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia", <i>The Journal of Urology</i> , <u>148</u> :1467-1474 (1992)
C10	Reuther and Aagaard, " α -Adrenergic Blockade in the Diagnosis of Detrusor Instability Secondary to Infravesical Obstruction", <i>Urologia Internationalis</i> , <u>39</u> :312-313 (1984)
C11	Serels and Stein, "Prospective Study Comparing Hyoscyamine, Doxazosin, and Combination Therapy for the Treatment of Urgency and Frequency in Women", <i>Neurourology and Urodynamics</i> , <u>17</u> (1):31-36 (1998)
C12	Schwinn et al., "Cloning and Pharmacological Characterization of Human Alpha-1 Adrenergic Receptors: Sequence Corrections and Direct Comparison with Other Species Homologues", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , <u>272</u> (1):134-142 (1995)
C13	Hieble et al., "International Union of Pharmacology X. Recommendation for Nomenclature of α_1 -Adrenoceptors: Consensus Update", <i>Pharmacological Reviews</i> , <u>47</u> (2):267-270 (1995)
C14	Goepel et al., "Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate", <i>Urological Research</i> , <u>25</u> (3):199-206 (1997)
C15	Hieble et al., "In vitro characterization of the α -adrenoceptors in human prostate", <i>European Journal of Pharmacology</i> , <u>107</u> (2):111-117 (1985)
C16	Chapple et al., "Characterisation of Human Prostatic Adrenoceptors using Pharmacology Receptor Binding and Localisation", <i>British Journal of Urology</i> , <u>63</u> :487-496 (1989)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION		Docket No.: RLL-459US	Serial No.: 10/593,939
		Applicants: CHUGH et al.	
		Filed: 2/25/2006	Group: 1617

C17	Price et al., "Identification, Quantification, and Localization of mRNA for Three Distinct Alpha ₁ Adrenergic Receptor Subtypes in Human Prostate", <i>The Journal of Urology</i> , <u>150</u> :546-551 (1993)
C18	Forray et al., "The α_1 -Adrenergic Receptor that Mediates Smooth Muscle Contraction in Human Prostate Has the Pharmacological Properties of the Cloned Human α_{1C} Subtype", <i>Molecular Pharmacology</i> , <u>45</u> :703-708 (1994)
C19	Lepor et al., "A Comparison of the Binding and Functional Properties of Alpha-1 Adrenoceptors and Area Density of Smooth Muscle in the Human, Canine and Rat Prostates", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , <u>270</u> (2):722-727 (1994)
C20	Muramatsu et al., "Pharmacological characterization of α_1 -adrenoceptor subtypes in the human prostate: functional and binding studies", <i>British Journal of Urology</i> , <u>74</u> :572-578, (1994)
C21	Daniels et al., "Human cloned α_{1A} -adrenoceptor isoforms display α_{1L} -adrenoceptor pharmacology in functional studies", <i>European Journal of Pharmacology</i> , <u>370</u> :337-343 (1999)
C22	Oesterling, "The Origin and Development of Benign Prostatic Hyperplasia An Age-Dependent Process", <i>Journal of Andrology</i> , <u>12</u> (6):348-355 (1991)
C23	Michel, "Potential Role of α_1 -Adrenoceptors in the Aetiology of LUTS", <i>European Urology Supplements</i> , <u>1</u> (9):5-13 (2002)
C24	Hieble and Ruffolo, Jr., "Recent advances in the identification of α_1 - and α_2 -adrenoceptor subtypes: therapeutic implications", <i>Expert Opinion on Investigational Drugs</i> , <u>6</u> (4):367-387 (1997)
C25	Young et al., "Congenital obstruction of the posterior urethra", <i>The Journal of Urology</i> , <u>167</u> :265-267 (2002)
C26	Staskin et al., "Overview Consensus Statement", <i>Urology</i> , <u>60</u> (Suppl. 5A):1-6 (2002)
C27	Caulfield and Birdsall, "International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors", <i>Pharmacological Reviews</i> , <u>50</u> (2):279-290 (1998)
C28	Hegde and Eglen, "Muscarinic Receptor Subtypes Modulating Smooth Muscle Contractility in the Urinary Bladder", <i>Life Sciences</i> , <u>64</u> (6/7):419-428 (1999)
C29	Fetscher et al., "M ₃ muscarinic receptors mediate contraction of human urinary bladder", <i>British Journal of Pharmacology</i> , <u>136</u> (5):641-644 (2002)
C30	Yamanishi et al., "Which muscarinic receptor is important in the bladder?", <i>World Journal of Urology</i> , <u>19</u> (5):299-306 (2001)
C31	Sullivan and Abrams, "Pharmacological Management of Incontinence", <i>European Urology</i> , <u>36</u> (Suppl. 1):89-95 (1999)
C32	Lozewicz, "Bladder outflow obstruction induced by ipratropium bromide", <i>Postgraduate Medical Journal</i> , <u>65</u> (762):260-261 (1989)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-459US	Serial No.: 10/593,939
	Applicants: CHUGH et al.	
	Filed: 2/25/2006	Group: 1617

C33	Abrams et al., "Safety of tolterodine in men with bladder outlet obstruction (BOO) and symptomatic detrusor overactivity", <i>European Urology Supplements</i> , <u>1</u> :132, Abstract 520 (2002)
C34	Bundgaard, H. (ed.). (1995). <i>Design of Prodrugs</i> . Elsevier.
C35	Michel et al., "Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned α_1 -adrenoceptor subtypes and in human prostate", <i>Journal of Autonomic Pharmacology</i> , <u>16</u> :21-28 (1996)
C36	Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , <u>64</u> (25):2351-2358 (1999)
C37	Jeppesen et al., "1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0 ^{2,6}]heptanes as New Potent Muscarinic M ₁ Agonists: Structure-Activity Relationship for 3-Aryl-2-propyn-1-yloxy and 3-Aryl-2-propyn-1-ylthio Derivatives", <i>Journal of Medicinal Chemistry</i> , <u>42</u> (11):1999-2006 (1999)
C38	Kenny et al., "Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia," <i>Journal of Medicinal Chemistry</i> , <u>40</u> (9):1293-1315 (1997)
C39	Athanasiopoulos et al., "Combination Treatment with an α -Blocker Plus an Anticholinergic for Bladder Outlet Obstruction: A Prospective, Randomized, Controlled Study", <i>The Journal of Urology</i> , <u>169</u> :2253-2256 (2003)
C40	Ranjan et al., "Comparative study of human steroid 5 α -reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride", <i>Life Sciences</i> , <u>71</u> (2):115-126 (2002)
C41	Andriole and Kirby, "Safety and Tolerability of the Dual 5 α -Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia", <i>European Urology</i> , <u>44</u> (1):82-88 (2003)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	